AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1579327
Drug: hCG administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG administration (2500 IU on days 3, 6, and 9 after ovulatory dose of 10,000 IU hCG)
Trial: 1579327
Drug: Non-treatment cycles
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment cycles (no luteal phase support)
Trial: 1579327
Drug: Non-treatment cycles
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment cycles
Trial: 3907322
Drug: Diltiazem (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (360 mg/day, administered 2 times a day)
Trial: 31515555
Drug: Capecitabine +
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine + oxaliplatin + bevacizumab or another reintroduction treatment
Trial: 30099829
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of cortisol
Trial: 18332313
Drug: Voriconazole, 1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole, 1%, eyedrops administered hourly for 4 doses
Trial: 18332313
Drug: Voriconazole, 1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole, 1%, eyedrops administered every 6 hours for 3 days
Trial: 15973769
Drug: Chronic hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic hepatitis B patients without lamivudine treatment
Trial: 1699989
Drug: Hydroxyzine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (100 mg/day)
Trial: 1699989
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg/day)
Trial: 31605900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SH + FR
Trial: 24164645
Drug: Intensive oral
RxNorm normalized name: Uricalm Intensive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive oral hygiene regimen including dental prophylaxis at baseline and oral hygiene instructions at baseline, 4 and 8 weeks.
Trial: 15377133
Drug: Terminalia arjuna
RxNorm normalized name: terminalia arjuna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terminalia arjuna (500 mg q8h)
Trial: 11482921
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of abciximab and stenting as an adjunct to PTCA
Trial: 9683836
Drug: Ceftazidime +
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime + amikacin + teicoplanin (6 mg/kg once a day)
Trial: 9683836
Drug: Ceftazidime +
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime + amikacin + vancomycin (30 mg/kg/day every 6 h)
Trial: 7810811
Drug: Halofantrine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (24 mg/kg or 72 mg/kg)
Trial: 3175849
Drug: Intracavitary high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavitary high-dose rate iridium irradiation
Trial: 3175849
Drug: Intracavitary high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavitary high-dose rate iridium irradiation (younger patients)
Trial: 3175849
Drug: Intracavitary high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavitary high-dose rate iridium irradiation (older patients, 70 years and more)
Trial: 3175849
Drug: Intracavitary high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavitary high-dose rate iridium irradiation (tumor grading 1)
Trial: 3175849
Drug: Intracavitary high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavitary high-dose rate iridium irradiation (tumor grading 2 and 3)
Trial: 31953583
Drug: Positive risk
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive risk encouragement (e.g., 'You are cool if you continue')
Trial: 31953583
Drug: Negative risk
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative risk encouragement (e.g., 'You are a softy if you do not continue')
Trial: 28688742
Drug: Clozapine 300mg/day
RxNorm normalized name: CLOZAPINE 300MG/DAY TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 300mg/day (monotherapy)
Trial: 8723572
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 600 IU/kg administered intravenously twice weekly for 3 weeks (in conjunction with oral iron supplementation)
Trial: 1691132
Drug: Cyclic alternating
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic alternating drugs (DNR + VCR + Ara-C)
Trial: 508556
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg three times daily dipyridamole + 180 mg ASA
Trial: 508556
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg three times daily dipyridamole + 120 mg ASA daily
Trial: 508556
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dipyridamole three times daily + 60 mg ASA
Trial: 508556
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of dipyridamole and ASA
Trial: 508556
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of ASA in combination with dipyridamole
Trial: 27989693
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of artificial tear containing dextran 70 (1mg/ml) and hypromellose (3mg/ml)
Trial: 23645328
Drug: Prospective ECG-triggered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective ECG-triggered sequential CCTA
Trial: 19723649
Drug: Lapuleucel-T (APC8024)
RxNorm normalized name: Lapuleucel-t
DrugBank: Lapuleucel-t (DB19117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapuleucel-T (APC8024) administered via leukapheresis and infusions in weeks 0, 2, and 4.
Trial: 10463739
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (nadroparin) - one daily subcutaneous injection, dosage adapted to body-weight
Trial: 10463739
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (nadroparin)
Trial: 7640875
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (120 mg single dose or 90 mg daily for 23 days)
Trial: 27716162
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behavioral therapy (CBT-E)
Trial: 25425451
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (metformin followed by sulfonylurea and glargine insulin)
Trial: 23171911
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hydrocortisone orally
Trial: 23171911
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hydrocortisone orally in BPD patients with co-morbid PTSD
Trial: 23171911
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hydrocortisone orally in BPD patients with co-morbid MDD
Trial: 11758322
Drug: Simultaneous bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous bolus injection of 2% lidocaine 2 ml with infusion of propofol
Trial: 11758322
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of saline 2 ml, 10 s before propofol infusion
Trial: 11758322
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of lidocaine 2 ml, 10 s before propofol infusion
Trial: 11758322
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of saline 2 ml, 10 s before propofol infusion (control group)
Trial: 11758322
Drug: Simultaneous bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous bolus injection of lidocaine with propofol
Trial: 2928745
Drug: Rinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with test agents after brushing with amine fluoride dentifrice (Elmex)
Trial: 28525984
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus Fermentum CECT5716, daily for 8 weeks
Trial: 23149845
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B therapy (FAB/LMB 96 study)
Trial: 18285717
Drug: Cirrhotic patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cirrhotic patients not responding or relapsing after treatment
Trial: 10637531
Drug: VOCs at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VOCs at 25 mg/m(3) for four hours
Trial: 10637531
Drug: VOCs at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VOCs at 50 mg/m(3) for four hours
Trial: 8317063
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of a polyethylene glycol solution (out-patient)
Trial: 8317063
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of a polyethylene glycol solution (in-patient)
Trial: 16204433
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg)
Trial: 2446061
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg) plus Hydrochlorothiazide (25 mg)
Trial: 30325939
Drug: AL-335 800
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 800 mg QD in non-cirrhotic, GT1-4-infected subjects
Trial: 30325939
Drug: AL-335 800
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 800 mg QD in GT1-infected cirrhotic subjects
Trial: 30325939
Drug: AL-335 (100-1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 (100-1,200 mg) in healthy volunteers
Trial: 30325939
Drug: AL-335 (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 (400, 800, 1,200 mg) in HCV-infected subjects
Trial: 30325939
Drug: AL-335 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 (400 mg) in fed state
Trial: 30325939
Drug: AL-335 (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 (1,200 mg) in fasted state
Trial: 28391393
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract 600 mg day-1
Trial: 28391393
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract 900 mg day-1
Trial: 28391393
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract 300 mg day-1
Trial: 28391393
Drug: No dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dose
Trial: 26052874
Drug: Clinician feedback
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician feedback intervention (CCFS) consisting of weekly performance feedback to clinicians and a clinical feedback report.
Trial: 23411609
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg daily
Trial: 22332579
Drug: Oral glucosamine
RxNorm normalized name: glucosamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucosamine hydrochloride (1.44 g daily) + intraarticular hyaluronate injection
Trial: 14580925
Drug: BAY 19-8004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 19-8004 (5 mg once daily)
Trial: 29526243
Drug: Standard cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cancer treatment plus the ANITA program (integrative Tai Chi program including peer support, health education, and Tai Chi Ruler exercise)
Trial: 29526243
Drug: Standard cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cancer treatment alone
Trial: 22648913
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg (test formulation)
Trial: 22648913
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg (reference formulation)
Trial: 20478402
Drug: n‐acetylcysteine pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐acetylcysteine pretreatment before a culture‐guided antibiotic regimen
Trial: 17628824
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of sodium bicarbonate (NaHCO3)
Trial: 17628824
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of calcium carbonate (CaCO3)
Trial: 12027195
Drug: Delirium-free protocol
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delirium-free protocol (DFP) group with diazepam injection at 20:00 h and continuous infusion of flunitrazepam and pethidine for 8 hours for the first three nights postoperatively
Trial: 2286596
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg bd, intravenous for 3 days followed by oral for 7-10 days)
Trial: 2286596
Drug: Amoxycillin/clavulanate (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate (intravenous for 3 days followed by oral for 7-10 days)
Trial: 23868279
Drug: Modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint‐induced movement therapy
Trial: 23868279
Drug: Dose‐matched conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐matched conventional treatment
Trial: 17568029
Drug: Fluconazole 6
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 6 mg/kg
Trial: 17568029
Drug: Fluconazole 3
RxNorm normalized name: Fluconazole 3 mg/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 3 mg/kg
Trial: 12113651
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1.0% cream applied twice daily for 3 weeks in adults
Trial: 12113651
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1.0% cream applied twice daily for 6 weeks in infants and children
Trial: 12113651
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1.0% cream
Trial: 12113651
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1.0% cream (intermittent long-term use)
Trial: 12113651
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus 1.0% cream for 1 year
Trial: 10569156
Drug: Topical intrastromal
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intrastromal steroid (prednisolone sodium phosphate 1% solution) applied on the undersurface of the cap immediately after it was reflected.
Trial: 10569156
Drug: Standard LASIK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard LASIK medication protocol (no steroid application).
Trial: 8545530
Drug: Flumazenil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 1.0 mg
Trial: 31975316
Drug: Red clover
RxNorm normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red clover preparation (Promensil® Forte) 80 mg/day for 24 months
Trial: 31975316
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one oral tablet/day without active ingredient)
Trial: 22071707
Drug: Uncalibrated protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncalibrated protein intake (g/d) (20% increment)
Trial: 22071707
Drug: Biomarker-calibrated protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-calibrated protein intake (g/d) (20% increment)
Trial: 22071707
Drug: Uncalibrated protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncalibrated protein intake (g/d) (20% increment) after adjustment for BMI
Trial: 11674922
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treated only with drugs)
Trial: 1357295
Drug: Intravenous adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adrenaline (0.1 microgram/kg)
Trial: 3908500
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of ciramadol
Trial: 3908500
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of ciramadol
Trial: 3908500
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of codeine
Trial: 23979965
Drug: Besifovir 90
RxNorm normalized name: Besifovir
DrugBank: Besifovir (DB15671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir 90 mg daily
Trial: 23979965
Drug: Besifovir 150
RxNorm normalized name: Besifovir
DrugBank: Besifovir (DB15671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir 150 mg daily
Trial: 16230074
Drug: Entecavir 0.5
RxNorm normalized name: entecavir 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg daily
Trial: 12654753
Drug: Azithromycin 1000
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000 mg once daily for 3 days
Trial: 11314681
Drug: Ritanserin 5
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin 5 mg
Trial: 1715125
Drug: Imazodan 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imazodan 2 mg administered twice daily
Trial: 1715125
Drug: Imazodan 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imazodan 5 mg administered twice daily
Trial: 1715125
Drug: Imazodan 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imazodan 10 mg administered twice daily
Trial: 6869493
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional therapies continued)
Trial: 26821623
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg intravenous CsA
Trial: 24556041
Drug: FOLFOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (oxaliplatin 85 mg/m², leucovorin 200 mg/m², bolus fluorouracil 400 mg/m², infusional fluorouracil 1600 mg/m²)
Trial: 24556041
Drug: Fluorouracil and
RxNorm normalized name: Fluorouracil and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil and cisplatin (fluorouracil 1000 mg/m² per day for 4 days and cisplatin 75 mg/m² on day 1)
Trial: 16134467
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for high-risk prethreshold ROP
Trial: 20385926
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for Type 1 eyes
Trial: 20385926
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for Type 2 eyes
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 0 to 0.49 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 0.50 to 0.99 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 1.00 to 1.49 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 1.50 to 1.99 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 2.00 to 2.49 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 2.50 to 2.99 ng/mL